OBJECTIVES: To evaluate the association of circulating sex steroid hormones and sex hormone binding globulin (SHBG) with lower urinary tract symptoms (LUTS). METHODS: We included 260 men, 60 years old or older, who participated in Phase 1 (1988 to 1991) of the Third National Health and Nutrition Examination Survey and for whom surplus serum was available. We measured the serum concentrations of testosterone, androstanediol glucuronide (AAG), estradiol, and SHBG. Free testosterone was calculated from the circulating testosterone, SHBG, and albumin. The cases (n = 128) were men with two to four symptoms (nocturia, hesitancy, incomplete emptying, and weak stream), but who had never undergone noncancer prostate surgery. The controls (n = 132) were men who neither had symptoms nor had undergone noncancer prostate surgery. We adjusted for age, race/ethnicity, waist circumference, cigarette smoking, alcohol consumption, and physical activity in logistic regression models and used sampling weights. RESULTS: The cases had statistically significantly greater AAG and estradiol concentrations than did the controls. After multivariate adjustment, the men in the top tertile of AAG (odds ratio 2.62, 95% confidence interval 1.12 to 6.14) had a greater risk of LUTS compared with men in the bottom two tertiles. Also, men with a greater estradiol concentration (odds ratio 1.78, 95% confidence interval 0.91 to 3.49) and a greater estradiol/SHBG molar ratio (odds ratio 2.41, 95% confidence interval 1.39 to 4.17) had a greater risk of LUTS than did men with lower concentrations. No consistent associations were seen for circulating testosterone, free testosterone, or SHBG. CONCLUSIONS: In this cross-sectional study representative of older U.S. men, circulating AAG, a metabolite of dihydrotestosterone, and estradiol were associated with an increased risk of having LUTS.
OBJECTIVES: To evaluate the association of circulating sex steroid hormones and sex hormone binding globulin (SHBG) with lower urinary tract symptoms (LUTS). METHODS: We included 260 men, 60 years old or older, who participated in Phase 1 (1988 to 1991) of the Third National Health and Nutrition Examination Survey and for whom surplus serum was available. We measured the serum concentrations of testosterone, androstanediol glucuronide (AAG), estradiol, and SHBG. Free testosterone was calculated from the circulating testosterone, SHBG, and albumin. The cases (n = 128) were men with two to four symptoms (nocturia, hesitancy, incomplete emptying, and weak stream), but who had never undergone noncancer prostate surgery. The controls (n = 132) were men who neither had symptoms nor had undergone noncancer prostate surgery. We adjusted for age, race/ethnicity, waist circumference, cigarette smoking, alcohol consumption, and physical activity in logistic regression models and used sampling weights. RESULTS: The cases had statistically significantly greater AAG and estradiol concentrations than did the controls. After multivariate adjustment, the men in the top tertile of AAG (odds ratio 2.62, 95% confidence interval 1.12 to 6.14) had a greater risk of LUTS compared with men in the bottom two tertiles. Also, men with a greater estradiol concentration (odds ratio 1.78, 95% confidence interval 0.91 to 3.49) and a greater estradiol/SHBG molar ratio (odds ratio 2.41, 95% confidence interval 1.39 to 4.17) had a greater risk of LUTS than did men with lower concentrations. No consistent associations were seen for circulating testosterone, free testosterone, or SHBG. CONCLUSIONS: In this cross-sectional study representative of older U.S. men, circulating AAG, a metabolite of dihydrotestosterone, and estradiol were associated with an increased risk of having LUTS.
Authors: Samuel Thomas; Ling Hao; Kellen DeLaney; Dalton McLean; Laura Steinke; Paul C Marker; Chad M Vezina; Lingjun Li; William A Ricke Journal: J Proteome Res Date: 2020-03-16 Impact factor: 4.466
Authors: Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; George G Klee; Michael M Lieber; Steven J Jacobsen Journal: Am J Epidemiol Date: 2011-03-02 Impact factor: 4.897
Authors: Delores J Grant; Cathrine Hoyo; Shannon D Oliver; Leah Gerber; Katie Shuler; Elizabeth Calloway; Alexis R Gaines; Megan McPhail; Jonathan N Livingston; Ricardo M Richardson; Joellen M Schildkraut; Stephen J Freedland Journal: Genet Test Mol Biomarkers Date: 2012-10-25
Authors: Meredith S Shiels; Sabine Rohrmann; Andy Menke; Elizabeth Selvin; Carlos J Crespo; Nader Rifai; Adrian Dobs; Manning Feinleib; Eliseo Guallar; Elizabeth A Platz Journal: Cancer Causes Control Date: 2009-03-10 Impact factor: 2.506